This week, we welcome back Keith Grossman. Keith has been a leader in the medical technology industry for more than 35 years. He is currently the Chairman of the Board of Nevro Corporation (NVRO), where he was previously President and CEO from 2019 through April 2023.

Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value, and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President, and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value before his arrival.

Prior to Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company.

Prior to Thoratec, he held a number of commercial and general management roles with companies, including SulzerMedica and American Hospital Supply Corp.

He currently also serves as Vice Chairman of Alcon, Inc., and is on the board of Outset Medical, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc, and a number of privately held medical device companies. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.